Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BiVictriX Therapeutics PLC (GB:BVX)
LSE:BVX
Holding GB:BVX?
Track your performance easily
BVX Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range7.00p - 14.25p
Previous Close10p
Volume0.00
Average Volume (3M)252.91K
Market Cap
£8.25M
Enterprise Value5.26M
Total Cash (Recent Filing)£3.29M
Total Debt (Recent Filing)£295.00K
Price to Earnings (P/E)―
Beta-0.34
Next Earnings
Mar 10, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding82,526,088
10 Day Avg. Volume497,349
30 Day Avg. Volume252,910
Standard Deviation0.16
R-Squared0.01
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)333.33
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BiVictriX Therapeutics PLC News
PremiumCompany Announcements
Spreadex LTD Adjusts Stake in BiVictriX Therapeutics
PremiumCompany Announcements
BiVictriX Shifts to Private Sector, Ends AIM Trading
PremiumCompany Announcements
BiVictriX Therapeutics Unveils Promising Cancer Drug Data
PremiumCompany Announcements
BiVictriX Reports Major Shift in Share Ownership
PremiumCompany Announcements
BiVictriX Therapeutics Sees Major Voting Rights Shift
PremiumCompany Announcements
BiVictriX Director Trades Shares, Company Advances Cancer Therapy
PremiumCompany Announcements
BiVictriX Therapeutics Passes Key ResolutionsPremiumCompany Announcements
BiVictriX Therapeutics Stake Shift by Spreadex LTDOptions Prices
Currently, No data available
---
Ownership Overview
3.47%
Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
96.53% Public Companies and
Individual Investors
BVX FAQ
What was BiVictriX Therapeutics PLC’s price range in the past 12 months?
BiVictriX Therapeutics PLC lowest share price was 7.00p and its highest was 14.25p in the past 12 months.
What is BiVictriX Therapeutics PLC’s market cap?
Currently, no data Available
When is BiVictriX Therapeutics PLC’s upcoming earnings report date?
BiVictriX Therapeutics PLC’s upcoming earnings report date is Mar 10, 2025 which is in 126 days.
How were BiVictriX Therapeutics PLC’s earnings last quarter?
BiVictriX Therapeutics PLC released its earnings results on Aug 01, 2024. The company reported -0.018p earnings per share for the quarter, missing the consensus estimate of N/A by -0.018p.
Is BiVictriX Therapeutics PLC overvalued?
According to Wall Street analysts BiVictriX Therapeutics PLC’s price is currently Overvalued.
Does BiVictriX Therapeutics PLC pay dividends?
BiVictriX Therapeutics PLC does not currently pay dividends.
What is BiVictriX Therapeutics PLC’s EPS estimate?
BiVictriX Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BiVictriX Therapeutics PLC have?
BiVictriX Therapeutics PLC has 82,526,085 shares outstanding.
What happened to BiVictriX Therapeutics PLC’s price movement after its last earnings report?
BiVictriX Therapeutics PLC reported an EPS of -0.018p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BiVictriX Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:BVX
---
BiVictriX Therapeutics PLC Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.57%
12-Months-Change
Fundamentals
Return on Equity
-103.99%
Trailing 12-Months
Asset Growth
-13.77%
Trailing 12-Months
Company Description
BiVictriX Therapeutics PLC
BiVictriX Therapeutics PLC is a drug development company. It has developed its proprietary Bi-Cygni technology which utilises Antibody Drug Conjugates for the treatment of various cancers including Acute Myeloid Leukaemia.
---
Technical Analysis
---